|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 9/28 | (2006.01) |
| A61K 9/20 | (2006.01) | ||
| A61K 31/519 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2654736 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11849974.8 |
| Date of filing the European patent application | 2011-12-20 | |
| (97) | Date of publication of the European application | 2013-10-30 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-01 |
| (46) | Date of publication of the claims translation | 2020-09-25 |
| (86) | Number | PCT/US2011/066021 |
| Date | 2011-12-20 |
| (87) | Number | WO 2012/088033 |
| Date | 2012-06-28 |
| (30) | Number | Date | Country code |
| 201061424967 P | 2010-12-20 | US |
| (72) |
DeMARINI, Douglas, J., US
LE, Ngocdiep, T., US
HENRIQUEZ, Francisco, US
WANG, Lihong, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Nauja farmacinė kompozicija |
| NOVEL PHARMACEUTICAL COMPOSITION |
| Payment date | Validity (years) | Amount | |
| 2024-11-22 | 14 | 289.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2025-04-08 |